| Literature DB >> 31360800 |
Matthew Susko1, Yao Yu1, Lijun Ma1, Jean Nakamura1, Shannon Fogh1, David R Raleigh1, Encouse Golden1, Philip V Theodosopoulos2, Michael W McDermott2, Penny K Sneed1, Steve E Braunstein1.
Abstract
PURPOSE: The incidence of brain metastases is increasing as a result of more routine diagnostic imaging and improved extracranial systemic treatment strategies. As noted in recent consensus guidelines, postoperative stereotactic radiosurgery (SRS) to the resection cavity has lower rates of local control than whole brain radiation therapy but improved cognitive outcomes. Further analyses are needed to improve local control and minimize toxicity. METHODS AND MATERIALS: Patients receiving SRS to a resection cavity between 2006 and 2016 were retrospectively analyzed. Presurgical variables, including tumor location, diameter, dural/meningeal contact, and histology, were collected, as were SRS treatment parameters. Patients had routine follow-up with magnetic resonance imaging, and those noted to have local failure were further assessed for the recurrence location, distance from the target volume, and dosimetric characteristics.Entities:
Year: 2019 PMID: 31360800 PMCID: PMC6639748 DOI: 10.1016/j.adro.2019.03.002
Source DB: PubMed Journal: Adv Radiat Oncol ISSN: 2452-1094
Figure 1Representative resection cavity (A) as outlined on the day of stereotactic radiosurgery (yellow) with isodose lines from 100% (red) to 50% (blue); (B) contour of a resection cavity recurrence with centroid (pink with red point marker) and serial 1 mm isotropic expansions of the resection cavity (blue, green, orange) created from the day of stereotactic radiosurgery contour (yellow). This was classified as a marginal recurrence because it fell in the zone receiving between 50% and 100% of the prescription dose, with the centroid 3 mm from the edge of the resection cavity.
Tumor characteristics
| Resected tumor characteristics | |||
|---|---|---|---|
| No recurrence | Recurrence | ||
| Age | 60 | 52 | .09 |
| Sex | .747 | ||
| Male | 25 | 5 | |
| Female | 23 | 7 | |
| Histology | .03 | ||
| Non-small cell lung cancer | 18 | 3 | |
| Breast | 9 | 3 | |
| Melanoma | 9 | 1 | |
| Colorectal | 0 | 3 | |
| RCC | 5 | 0 | |
| Other | 7 | 2 | |
| Tumor location | .59 | ||
| Supratentorial | 44 | 10 | |
| Infratentorial | 4 | 2 | |
| Dural/meningeal contact | .025 | ||
| Yes | 32 | 12 | |
| No | 16 | 0 | |
| Surgical resection | .33 | ||
| Gross total resection | 42 | 12 | |
| Sub/near total resection | 6 | 0 | |
Abbreviation: RCC = renal cell carcinoma.
Median treatment parameters with interquartile range
| Treatment parameters | No recurrence | Recurrence | |
|---|---|---|---|
| Target volume (cm3) | 5.17 (3.43-8.77) | 6.65 (5.83-9.52) | .24 |
| Prescription isodose volume (cm3) | 7.02 (4.44-10.72) | 8.53 (7.78-12.01) | .26 |
| Quadratic mean diameter (cm) | 2.50 (2.08-2.96) | 2.37 (2.35-3.05) | .41 |
| Conformity index | 1.31 (1.20-1.41) | 1.26 (1.18-1.43) | .80 |
| Modified conformity index | 1.28 (1.18-1.40) | 1.22 (1.15-1.43) | .59 |
| Dose (Gy) | 17 (16-18) | 16.5 (16-17) | .13 |
Mean D20, D50, D80, and D100 for infield, marginal, and out-of-field recurrences
| Recurrence characteristics | ||||||
|---|---|---|---|---|---|---|
| D20 | D50 | D80 | D100 | Median centroid distance (mm) | Range (mm) | |
| Infield (n = 5) | 21.2 | 19.7 | 17.8 | 13.4 | -- | -- |
| Marginal (n = 5) | 15.4 | 9.1 | 6.3 | 3.5 | 3 | 2-5 |
| Out-of-field (n = 4) | 8.4 | 5.1 | 3.6 | 2.2 | 5.5 | 4-8 |
Abbreviation: Dx = dose that encompasses x% of the recurrence volume.
Two of 12 cavities with recurrence had 2 separate foci of recurrence.
Figure 2Dose-volume histogram of the mean dose received by the region of the contoured recurrence.